EFFICACY AND SAFETY OF PONATINIB USED IN FRAIL CHRONIC PHASE CHRONIC MYELOID LEUKEMIA PATIENTS OUTSIDE OF CLINICAL TRIALS

被引：0
|
作者：
Breccia, M. [1 ]
Abruzzese, E. [2 ]
Accurso, V. [3 ]
Castagnetti, F. [4 ]
Galimberti, S. [5 ]
Bonifacio, M. [6 ]
Gangemi, D. [7 ]
La Barba, G.
Sora, F. [8 ]
Tiribelli, M. [9 ]
Iurlo, A. [10 ]
Luciano, L. [11 ]
Gozzini, A. [12 ]
Pezzullo, L.
Rossi, A. Russo [13 ]
Sgherza, N. [14 ]
Foa, R. [1 ]
机构：
[1] Sapienza Univ, Dept Cellular Biotechnol & Hematol, Policlin Umberto I, Hematol, Rome, Italy
[2] S Eugenio Hosp, Rome, Italy
[3] Policlin Giaccone, Hematol, Palermo, Italy
[4] Univ Bologna, Inst Hematol L&A Seragnoli, Univ Hosp, Bologna, Italy
[5] Pisa Univ, Hematol, Pisa, Italy
[6] Univ Verona, Sect Hematol, Dept Med, Verona, Italy
[7] Fabrizio Spaziano Hosp, Frosinone, Italy
[8] Cattolica Sacro Cuore Univ, Rome, Italy
[9] Udine Univ, Hematol, Udine, Italy
[10] Univ Milan, IRCCS Ca Granda Maggiore Policlin Hosp Fdn, Milan, Italy
[11] Federico II Univ Naples, Naples, Italy
[12] Univ Firenze, AOU Careggi, Florence, Italy
[13] Univ Bari, Hematol & Transplants Unit, Bari, Italy
[14] Casa Sollievo Sofferenza Hosp, San Giovanni Rotondo, Italy
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
P096
引用
收藏
页码：89 / 90
页数：2
相关论文
共 50 条
  • [21] Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials
    Suh, Koung Jin
    Lee, Ji Yun
    Shin, Dong-Yeop
    Koh, Youngil
    Bang, Soo-Mee
    Yoon, Sung-Soo
    Park, Seonyang
    Kim, Inho
    Lee, Jeong-Ok
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 106 (02) : 229 - 239
  • [22] Analysis of adverse events associated with dasatinib and nilotinib treatments in chronic-phase chronic myeloid leukemia patients outside clinical trials
    Koung Jin Suh
    Ji Yun Lee
    Dong-Yeop Shin
    Youngil Koh
    Soo-Mee Bang
    Sung-Soo Yoon
    Seonyang Park
    Inho Kim
    Jeong-Ok Lee
    International Journal of Hematology, 2017, 106 : 229 - 239
  • [23] Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase
    Michihide Tokuhira
    Yuta Kimura
    Keiji Sugimoto
    Tomonori Nakazato
    Maho Ishikawa
    Isao Fujioka
    Tomoiku Takaku
    Noriyoshi Iriyama
    Eriko Sato
    Hiroyuki Fujita
    Yoshihiro Hatta
    Norio Komatsu
    Norio Asou
    Masahiro Kizaki
    Tatsuya Kawaguchi
    Medical Oncology, 2018, 35
  • [24] Ponatinib As Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Jain, Preetesh
    Kantarjian, Hagop M.
    Jabbour, Elias
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Gachimova, Evguenia
    Ferrajoli, Alessandra
    Kornblau, Steven M.
    Ravandi, Farhad
    O'Brien, Susan
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
  • [25] Efficacy and safety of nilotinib therapy in patients with newly diagnosed chronic myeloid leukemia in the chronic phase
    Tokuhira, Michihide
    Kimura, Yuta
    Sugimoto, Keiji
    Nakazato, Tomonori
    Ishikawa, Maho
    Fujioka, Isao
    Takaku, Tomoiku
    Iriyama, Noriyoshi
    Sato, Eriko
    Fujita, Hiroyuki
    Hatta, Yoshihiro
    Komatsu, Norio
    Asou, Norio
    Kizaki, Masahiro
    Kawaguchi, Tatsuya
    MEDICAL ONCOLOGY, 2018, 35 (03)
  • [26] Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
    Cortes, Jorge E.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Quintas-Cardama, Alfonso
    Ravandi, Farhad
    Gachimova, Evguenia
    Estrov, Zeev
    Jabbour, Elias
    O'Brien, Susan
    Kantarjian, Hagop
    BLOOD, 2013, 122 (21)
  • [27] Ponatinib for the treatment of adult patients with resistant or intolerant Chronic-Phase Chronic Myeloid Leukemia
    Haddad, Fadi G.
    Issa, Ghayas C.
    Jabbour, Elias
    Yilmaz, Musa
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (07) : 751 - 758
  • [28] MANAGEMENT OF PONATINIB DOSING IN CHRONIC MYELOID LEUKEMIA PATIENTS
    Sacha, T.
    Szczepanek, E.
    JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2021, 72 (03): : 321 - 327
  • [29] Efficacy and Safety of Imatinib Mesylate for Patients in the First Chronic Phase of Chronic Myeloid Leukemia: Results of a Japanese Phase II Clinical Study
    Yasuo Morishima
    Michinori Ogura
    Miki Nishimura
    Fumiharu Yazaki
    Masami Bessho
    Hideaki Mizoguchi
    Shigeru Chiba
    Hisamaru Hirai
    Tetsuzo Tauchi
    Akio Urabe
    Masatomo Takahashi
    Kazunori Ohnishi
    Toshiya Yokozawa
    Nobuhiko Emi
    Masami Hirano
    Chihiro Shimazaki
    Shinji Nakao
    Yasukazu Kawai
    Masahiro Fujimoto
    Hirokuni Taguchi
    Itsuro Jinnai
    Ryuzo Ohno
    International Journal of Hematology, 2004, 80 : 261 - 266
  • [30] Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: Results of a Japanese phase II clinical study
    Morishima, Y
    Ogura, M
    Nishimura, M
    Yazaki, F
    Bessho, M
    Mizoguchi, H
    Chiba, S
    Hirai, H
    Tauchi, T
    Urabe, A
    Takahashi, M
    Ohnishi, K
    Yokozawa, T
    Emi, N
    Hirano, M
    Shimazaki, C
    Nakao, S
    Kawai, Y
    Fujimoto, M
    Taguchi, H
    Jinnai, I
    Ohno, R
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2004, 80 (03) : 261 - 266
12345